Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.55
Bid: 8.50
Ask: 8.60
Change: -0.14 (-1.59%)
Spread: 0.10 (1.176%)
Open: 8.58
High: 8.66
Low: 8.55
Prev. Close: 8.80
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Share Buyback Programme announced

22 Sep 2023 07:00

RNS Number : 2676N
Agronomics Limited
22 September 2023
 

22 September 2023

Agronomics Limited

("Agronomics" or the "Company")

Share Buyback Programme announced

The Board of Agronomics announces that it will execute an on-market Share buyback programme for an aggregate amount of up to £3 million (the "Buyback Programme"). The term of the Buyback Programme shall be 6 months, commencing on 2 October 2023. The Company intends to cancel any repurchased Shares under the programme unless used to cover obligations under share-based remuneration arrangements.

The Board notes that the price of the Company's Shares is currently significantly below the last reported net asset value per share ("NAV Per Share") of 15.8 pence and believes that the Buyback Programme will help reduce this discount. In particular, as reported on 2 August 2023, the Company's unaudited NAV Per Share as at 30 June 2023 was 15.8 pence per share (whereas the price of the Company's shares at close of business on 19 September 2023, was 9.9 pence per share, a discount of approximately 37.3%). The Company reports NAV Per Share on a quarterly basis within 90 days of the end of each calendar quarter ("Quarterly NAV Statement").

The Buyback Programme will be executed within the limitations of the existing authority in the Company's Articles of Association. The Board will authorise each buyback transaction during the Buyback Programme which will be undertaken by Cavendish Securities Plc as the Company's joint broker and each such transaction will be reported and announced once executed.

The Company has determined that in conducting the Buyback Programme it will not rely on the safe harbour conditions for trading set out in Article 3(2) and Article 3(3) of the Commission Delegated Regulation (EU) 2016/1052 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018) and, as such, the Company may purchase on any trading day materially in excess of 25 per cent of the average daily volume in the 20 trading days preceding the date on which the purchase is carried out.

The terms of the Buyback Programme are set out below:

Name of Programme

2023 Share Buyback Programme

Purpose of the Programme

To reduce the capital of the issuer

Duration of the Programme

2 October 2023 to 29 March 2024

Maximum amount allocated to the Programme

£3.0 million

Maximum monthly amount allocated to Programme

£500,000

Maximum price

 

The higher of:

a) the price of the last independent trade; and

b) the highest current independent purchase bid on the trading venue where the purchase is carried out,

SAVE THAT no share shall be bought back by the Company at a price per share higher than 75% of the last reported NAV Per Share published in the Company's most recent Quarterly NAV Statement.

There is no guarantee that the Buyback Programme will be implemented in full or that any purchases will be made.

As at the time of this announcement, the Company's total issued share capital consists of 993,153,870Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in treasury, therefore, the total number of Ordinary Shares carrying voting rights is 993,153,870.

The above figure 993,153,870may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

About Agronomics

Agronomics is the leading listed venture capital firm with a focus on cellular agriculture. The Company has established a portfolio of over 20 companies at the Pre-Seed to Series C stage in this rapidly advancing sector. It seeks to secure minority stakes in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals, as well as being fundamental to feeding the world's expanding population.

About Cellular Agriculture

Cellular Agriculture is the production of agriculture products directly from cells, as opposed to raising an animal for slaughter or growing crops. This encompasses cell culture to produce cultivated meat and materials, and fermentation processes that harness a combination of molecular biology, synthetic biology, tissue engineering and biotechnology to massively simplify production methods in a sustainable manner.

Over the coming decades, the source of the world's food supply traditionally derived from conventional agriculture is going to change dramatically. We have already witnessed the first wave of this shift with the consumer adoption of plant-based alternative proteins but today, we are on the cusp of an even bigger wave of change. This is being facilitated by advances in cellular agriculture. This change is necessary, given scientists' claims that if we maintain existing animal protein consumption patterns, then we will not meet the Paris Agreement's goal of limiting warming to 1.5.

AT Kearney, a global consultancy firm, projects that cultivated meat's market share will reach 35% by 2040. This combined with the Good Food Institute's estimate that a US $1.8 trillion investment will be required in order to produce just 10% of the world's protein using this technology, means that we are on the cusp of a multi-decade flow of capital to build out manufacturing facilities. Funding in the field of cellular agriculture is accelerating, however, still, less than US$ 5 billion has been invested worldwide since the industry's inception in 2016.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014, as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

For further information please contact:

Agronomics Limited

Beaumont Cornish Limited

Canaccord Genuity Limited

Cavendish Securities Plc

Peterhouse Capital Limited

SEC Newgate

The Company

Nomad

Joint Broker

Joint Broker

Joint Broker

Public Relations

Richard Reed

Denham Eke

Roland Cornish

James Biddle

Andrew Potts

Harry Rees

Alex Aylen (Head of Equities)

Giles Balleny

Michael Johnson

Lucy Williams

Charles Goodfellow

Bob Huxford

George Esmond

Anthony Hughes

Alice Cho

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

+44 (0) 207 523 8000

+44 (0) 207 397 8900

+44 (0) 207 469 0936

agronomics@secnewgate.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSNKDBPQBKDNCB
Date   Source Headline
26th Oct 20217:00 amRNSInSilico Medicine sale-Correction of sale proceeds
20th Oct 20218:00 amRNSAgronomics leads investment in California Cultured
12th Oct 20217:00 amRNSExercise of Warrants and Updated TVR
29th Sep 20217:00 amRNSAnnounces Sale of Oritain Shares
28th Sep 20217:00 amRNSNew Age Meats Announces US$ 25 million Series A
22nd Sep 20212:48 pmRNSPortfolio Company Update: Mosa Meat
20th Sep 20217:00 amRNSAgronomics leads VitroLabs Series A Funding
14th Sep 20217:00 amRNSPortfolio Company Update: Meatable
14th Sep 20217:00 amRNSPortfolio Company Update: BlueNalu
13th Sep 20218:00 amRNSSubscription in Formo’s US $50 million Fundraise
30th Jul 20215:34 pmRNSReplacement: Net Asset Valuation to 30 June 2021
30th Jul 202112:02 pmRNSNet Asset Value calculation to 31 June 2021
21st Jul 20211:15 pmRNSPortfolio Company Update: Shiok Meats Pte. Ltd
15th Jul 20217:00 amRNSWarrants to be traded on J P Jenkins
14th Jul 20217:00 amRNSTwo portfolio companies in XPRIZE semi-finals
13th Jul 20217:00 amRNSHalf Year Newsletter
25th Jun 20214:21 pmRNSPortfolio Company LIVEKINDLY Update
24th Jun 20215:03 pmRNSPortfolio Company Formo Update
24th Jun 20217:00 amRNSAnnounces the Sale of InSilico Medicine Inc Shares
28th May 202112:10 pmRNSResults of General Meeting, Issue of Equity & TVR
28th May 20217:00 amRNSAnnounces the Conversion of CellX SAFE
27th May 20217:00 amRNSBroker Option Results
25th May 20217:00 amRNSUpdate regarding Broker Option
20th May 20217:00 amRNSUpdate regarding Broker Option
13th May 20217:00 amRNSAnnounces Secondary Purchase of Shares in Meatable
12th May 20217:00 amRNSResult of Fundraising
11th May 202111:05 amRNSSecond Price Monitoring Extn
11th May 202111:00 amRNSPrice Monitoring Extension
11th May 202110:40 amRNSProposed Fundraise to raise £50 million
6th May 20212:30 pmRNSNew Consultancy Agreement with Shellbay
21st Apr 20218:30 amRNSInvestee Company Update: LegenDairy Foods
21st Apr 20217:00 amRNSNet Asset Value calculation to 31 March 2021
8th Apr 202110:47 amRNSInvestee Company Update: Solar Foods
30th Mar 20217:00 amRNSInvestee Company Update: LIVEKINDLY Fundraise
23rd Mar 20213:00 pmRNSMeatable Announces US$ 47 Million Financing
15th Mar 20212:06 pmRNSSecond Price Monitoring Extn
15th Mar 20212:01 pmRNSPrice Monitoring Extension
15th Mar 202111:05 amRNSSecond Price Monitoring Extn
15th Mar 202111:00 amRNSPrice Monitoring Extension
26th Feb 20217:00 amRNSPortfolio Company Update: LIVEKINDLY Collective
25th Feb 20217:00 amRNSAnnounces Further Investment in VitroLabs
18th Feb 20217:00 amRNSAnnounces Further Investment in Meatable
11th Feb 20217:00 amRNSInvestee Company Update: New Age Meats
3rd Feb 20217:00 amRNSResult of AGM
26th Jan 20217:00 amRNSHalf-year Report
20th Jan 20217:00 amRNSInvestee Company Update: BlueNalu Secures $60m
19th Jan 20213:33 pmRNSExercise of Warrants
18th Jan 20217:00 amRNSNet Asset Value calculation to 31 December 2020
16th Dec 20207:00 amRNSInvestment in SuperMeat
14th Dec 20207:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.